Claret Capital Partners
A London growth debt fund manager lending €2m to €100m, usually with a small warrant component, to venture-backed technology, life sciences and climate tech companies across Europe.
Considering finance for your business? Discuss the lender options.
Published band £2m to £100m, against the other 59 private-credit and direct-lending funds.
| Lender | Published band |
|---|---|
| Claret Capital Partners | £2m to £100m |
| The other private-credit and direct-lending funds | 28 of 59 publish a band; at the field's peak 23 of them cover the same facility size |
| The band this directory reads for | £3m to £15m |
The shaded field is the other 59 private-credit and direct-lending funds in this directory, taller where more of them publish a band covering that size. Claret Capital Partners’s bar is its own published range. A band is what a lender states it will do, not what it will do on a given credit.
What they do
Claret Capital Partners is an independent growth debt fund manager in London that lends to venture-backed companies across Europe from committed fund capital, and it describes itself as the continent's largest independent manager of its kind. The team began in 2013 as Harbert European Growth Capital, part of Harbert Management Corp, and spun out as Claret in 2020. Since 2013 it has invested more than €1.5bn in more than 210 companies across technology, life sciences and impact, recycling capital through successive fund vintages, and it has raised €1.3bn in total. In September 2026, Claret European Growth Capital Fund IV held its final close: with affiliated discretionary mandates the cycle raised €575m against a €500m target, from pension plans, insurers, family offices, public investors and, through an ELTIF structure, private wealth. A separate co-investment fund backed by British Business Investments targets high-growth, technology-enabled smaller UK businesses. The product is a growth loan of typically €2m to €100m, usually carrying warrants, positioned as less dilutive than an equity round.
Who they lend to
Claret lends to revenue-generating, high-growth companies with proven management teams, most of them backed by venture capital, and it counts the strength of the VC syndicate in its assessment. Its own M&A guidance puts the usual entry point at around €5m of annualised revenue for a B2B business and €10m for a consumer one, lower in deep tech and life sciences where IP validation is itself a milestone. There is no EBITDA floor, and cash burn is sized rather than refused. Technology covers software, marketplaces, consumer internet, fintech and hardware; life sciences runs from therapeutics and medical devices to diagnostics and digital health; climate and impact businesses complete the focus. It publishes no excluded sectors. Portfolio companies sit in the UK, Ireland, France, Germany, Spain, Sweden and Switzerland among others, plus the US, and recent life sciences lending includes late-stage financings for listed companies such as Inventiva and Carvolix.
How they structure a facility
The facility is a senior secured growth or venture debt term loan that typically amortises after an interest-only period, which Claret's guidance puts at 12 to 18 months on average among venture lenders, sometimes longer. Additional capacity can be structured in tranches linked to agreed milestones, with funding available at close. Deals usually carry a small equity component, typically warrants giving the lender an option to invest at a set price, generally the transaction price. Collateral is taken over IP, receivables and trademarks. Quantum turns on revenue, unit economics, cash burn, existing debt and sector, tested through ratios such as debt to ARR and debt to gross margin; for an acquisition Claret generally treats 40% of combined revenues as a practical maximum. Financial covenants may be added depending on the amount of leverage. Governance rights are light, with lenders typically taking board observer seats only. Claret does not publish its pricing, its tenor or a position on personal guarantees.
Published terms
- Pricing
- Not published
- Published by 1 of 60
- Speed to terms
- Two to three weeks to a term sheet, then about a month of due diligence; signed term sheet to committed capital typically about eight weeks
- Published by 8 of 60
- Sponsored or sponsorless
- Both - skewed to VC-/equity-backed companies; debt complementary to equity rather than private equity-buyout leverage
- Where they lend
- Pan-European; UK-founded (2013), London-HQ. Dedicated British Business Investments co-investment fund targets UK high-growth tech-enabled smaller businesses
- How they decide
- Investment committee (managing partners Bateman/Kampe historically on an investment committee of predecessor vehicles); delegated-authority detail unpublished
- Search funds and ETA
- No published route for search-fund or first-time acquirer borrowers
- Covenants
- Financial covenants may be needed depending on the amount of leverage; no standard covenant package published
- Published by 15 of 60
- Security
- Senior secured, with collateral over IP, receivables and trademarks; a small equity component, typically warrants, alongside
- Published by 12 of 60
- Term
- Tenor not published; Claret's guidance puts venture lenders' interest-only periods at 12 to 18 months on average, followed by amortisation
- Minimum turnover
- Generally €5m annualised revenue for B2B and €10m for consumer businesses, lower for deep tech and life sciences
As published by the lender and last reviewed October 2026. Terms quoted on a deal are set by the credit, not by a published band.
How a deal reaches them
Claret publishes no broker programme; a borrower or its adviser goes through the contact page or info@claret-capital.com, and the website is addressed to professional clients and eligible counterparties. Its guidance asks for a company to arrive lender-ready, with a structured data room, monthly financials for the prior two years, monthly forecasts for the next two including cash flow and balance sheet, customer and cohort analysis, KPI analysis and a CFO able to share data quickly. It tells founders to expect two to three weeks before a term sheet and then about a month of due diligence, and a July 2026 piece on late-stage therapeutics put signed term sheet to committed capital at about eight weeks. Investment professionals evaluate each case individually, and Claret tries to re-lend to the companies it already backs.
Where they fit in a lower-mid-market raise
Claret is the natural call for a venture-backed software, fintech, medical device, diagnostics or climate technology company raising £3m to £15m against revenue rather than earnings, whether to extend runway alongside or between equity rounds, reach a milestone before the next raise, or fund a bolt-on acquisition. A cash-flow direct lender cannot size a business with negative EBITDA; Claret sizes it on revenue, burn and the depth of the equity syndicate behind it. Its €2m entry point sits below the band and its €100m ceiling far above it, so a growing borrower can come back for follow-on money, as Paysend did with a US$25m follow-on in March 2026. Repeat lending is part of the model: Claret has lent several times to the same companies for M&A. Kreos, Salica and Palatine Growth Credit are its nearest comparators in growth and venture lending, all underwriting recurring revenue rather than earnings.
Where they are not the fit
Claret lends alongside equity to growth companies, which leaves a private-equity buyout of a cash-generative business, or a search-fund acquisition, without a route here. A company under roughly €5m of annualised B2B revenue, or €10m in consumer, is generally too early outside deep tech and life sciences, and Claret's own guidance says a business whose technology is not yet significantly de-risked is better served by equity. Warrants dilute existing shareholders, though far less than an equity round; a profitable owner-managed company can avoid that with a plain senior facility from a bank or cash-flow lender at lower cost. Claret does not publish its pricing, so the cost of the debt and the warrant cover is only known from a term sheet.
What rules a deal out
Stated limits, taken from Claret Capital Partners’s own published criteria. A limit is where a lender starts from, not where it always ends: several of these move on a strong enough credit.
- Not for cash-generative EBITDA buyouts or searcher acquisitions
- Borrower must be revenue-generating high-growth tech/life-science/climate; typically VC- or equity-backed
How they sit against the category
- Its published ceiling of £100m is among the 5 highest of the 60 private-credit funds here.
- It opens lower than almost all of them, at £2m.
- Like 59 of the 60, it publishes no indicative price; a margin comes from a conversation, not a page.
Counted across the 60 private-credit & direct-lending funds in this directory, on what each one publishes. What a lender discloses and what it will do are different things.
Recent activity on the public record
In July 2024, British Business Investments made a further commitment to Claret through a new co-investment fund for UK high-growth, technology-enabled smaller businesses; the amount was not disclosed. In September 2025, Fund IV held a second close above €350m. In March 2026, Claret committed €28m to the Stockholm-listed biotech Cinclus and made a US$25m follow-on investment in Paysend. In August 2026, it invested €30m in Carvolix, a listed French medical technology company. In September 2026, Fund IV reached its final close with 32% of the fund already deployed across 27 companies, and Claret provided a €25m growth debt facility to a Galway medical device company that had completed a €62.5m Series C earlier in the year. In October 2026, LearnUpon announced a $50m growth financing facility from Fund IV to fund product development, international expansion and acquisitions.
10 dated items, 2024 to 2026, numbered as listed below.
| No. | Date | Item |
|---|---|---|
| 01 | Jul 2024 | British Business Investments made a further commitment to Claret through a new co-investment fund for UK high-growth, technology-enabled smaller businesses. |
| 02 | 2025 | 12 new Fund IV investments incl. Fund Recs, Mindler, Montonio, PRODA, SIDES, ValueBlue, Yseop (Claret press release. |
| 03 | Sep 2025 | Fund IV (CEGCF IV) second close over EUR350m; total AUM over USD1bn; final close expected 2026 (Claret / Tech.eu. |
| 04 | Mar 2026 | Claret invested €28m in Cinclus, the Stockholm-listed biotech. |
| 05 | Mar 2026 | Claret made a US$25m follow-on investment in Paysend, the UK-based global payments infrastructure company. |
| 06 | Jun 2026 | Claret participated in a €130m financing for Inventiva. |
| 07 | Aug 2026 | Claret invested €30m in Carvolix, a listed French commercial and clinical-stage medical technology company, to fund commercialisation. |
| 08 | Sep 2026 | Claret provided a €25m growth debt facility to a Galway medical device company treating chronic rhinitis, following its €62.5m Series C. |
| 09 | Sep 2026 | Fund IV reached its final close; with affiliated discretionary mandates Claret raised €575m, comprising €440m of Fund IV commitments and €135m of mandates, above a €500m target. |
| 10 | Oct 2026 | LearnUpon announced a $50m growth financing facility from Claret's Fund IV to fund product development, international growth and acquisitions. |
On the record
July 2024: British Business Investments made a further commitment to Claret through a new co-investment fund for UK high-growth, technology-enabled smaller businesses.
2025: 12 new Fund IV investments incl. Fund Recs, Mindler, Montonio, PRODA, SIDES, ValueBlue, Yseop (Claret press release.
September 2025: Fund IV (CEGCF IV) second close over EUR350m; total AUM over USD1bn; final close expected 2026 (Claret / Tech.eu.
March 2026: Claret made a US$25m follow-on investment in Paysend, the UK-based global payments infrastructure company.
March 2026: Claret invested €28m in Cinclus, the Stockholm-listed biotech.
June 2026: Claret participated in a €130m financing for Inventiva.
August 2026: Claret invested €30m in Carvolix, a listed French commercial and clinical-stage medical technology company, to fund commercialisation.
September 2026: Fund IV reached its final close; with affiliated discretionary mandates Claret raised €575m, comprising €440m of Fund IV commitments and €135m of mandates, above a €500m target.
September 2026: Claret provided a €25m growth debt facility to a Galway medical device company treating chronic rhinitis, following its €62.5m Series C.
October 2026: LearnUpon announced a $50m growth financing facility from Claret's Fund IV to fund product development, international growth and acquisitions.
Questions this page answers
What is the minimum and maximum loan from Claret Capital Partners?
Claret Capital Partners says its loans typically range from €2m to €100m, with each opportunity evaluated case by case by its investment professionals.
As published at claret-capital.com
How much revenue does a company need to borrow from Claret Capital Partners?
Claret Capital Partners' guidance says a business generally needs around €5m of annualised revenue in B2B or €10m in consumer, with lower levels possible for deep tech or life science companies where IP validation is itself a major milestone.
As published at claret-capital.com
How long does Claret Capital Partners take to issue a term sheet?
Claret Capital Partners tells founders to expect two to three weeks before a term sheet, followed by a month of due diligence, and says a growth lending process runs faster than a growth equity process.
As published at claret-capital.com
Does Claret Capital Partners take warrants?
Usually. Claret Capital Partners says growth lending deals typically include a small equity component, generally warrants that give the lender an option to invest in equity at a set price, usually the transaction price.
As published at claret-capital.com
What security does Claret Capital Partners take on a growth loan?
Claret Capital Partners describes the collateral for growth debt as security over IP, receivables and trademarks. It publishes no position on personal guarantees.
As published at claret-capital.com
Can Claret Capital Partners fund an acquisition?
Yes. Claret Capital Partners calls M&A a core pillar of its European strategy, has lent several times to the same companies for acquisitions, and generally treats 40% of combined revenues as a practical maximum for growth debt.
As published at claret-capital.com
Is Claret Capital Partners regulated by the FCA?
Yes. Claret Capital Partners Limited, company number 12516001, is authorised and regulated by the Financial Conduct Authority under FRN 993228, and its website is aimed at professional clients and eligible counterparties.
As published at claret-capital.com
Does Claret Capital Partners lend to companies without a private-equity sponsor?
Yes. Claret Capital Partners lends to owner-managed and sponsor-backed borrowers alike, so a company with no private-equity backer is not out of scope on that ground.
Sources: british-business-bank.co.uk · claret-capital.com · Companies House
Terms used on this page: Term sheet · Amortisation · Sponsor · Direct lender
This profile is a curated reference note drawn from public sources, not financial advice or a recommendation. Appetite and terms change; a lender's fit for a given credit is established by approaching it, not inferred from a page.